首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1973040篇
  免费   143033篇
  国内免费   3974篇
耳鼻咽喉   28500篇
儿科学   64842篇
妇产科学   57529篇
基础医学   285776篇
口腔科学   55551篇
临床医学   167804篇
内科学   387964篇
皮肤病学   41681篇
神经病学   154885篇
特种医学   77904篇
外国民族医学   672篇
外科学   307510篇
综合类   42206篇
现状与发展   1篇
一般理论   525篇
预防医学   145381篇
眼科学   45630篇
药学   147291篇
  1篇
中国医学   3887篇
肿瘤学   104507篇
  2018年   18899篇
  2016年   16080篇
  2015年   18430篇
  2014年   25962篇
  2013年   39714篇
  2012年   53863篇
  2011年   57711篇
  2010年   34555篇
  2009年   32644篇
  2008年   55560篇
  2007年   59728篇
  2006年   60631篇
  2005年   59408篇
  2004年   57048篇
  2003年   55371篇
  2002年   54509篇
  2001年   88088篇
  2000年   90527篇
  1999年   77328篇
  1998年   21913篇
  1997年   19809篇
  1996年   19933篇
  1995年   18712篇
  1994年   17810篇
  1993年   16641篇
  1992年   61853篇
  1991年   60454篇
  1990年   59458篇
  1989年   57533篇
  1988年   53724篇
  1987年   52697篇
  1986年   50420篇
  1985年   48144篇
  1984年   36063篇
  1983年   31088篇
  1982年   18678篇
  1981年   16427篇
  1979年   34056篇
  1978年   23944篇
  1977年   20521篇
  1976年   19425篇
  1975年   21359篇
  1974年   25267篇
  1973年   24303篇
  1972年   23124篇
  1971年   21514篇
  1970年   20248篇
  1969年   19215篇
  1968年   18229篇
  1967年   16289篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
Farnesyltransferase (FTase) is one of the prenyltransferase family enzymes that catalyse the transfer of 15-membered isoprenoid (farnesyl) moiety to the cysteine of CAAX motif-containing proteins including Rho and Ras family of G proteins. Inhibitors of FTase act as drugs for cancer, malaria, progeria and other diseases. In the present investigation, we have developed two structure-based pharmacophore models from protein–ligand complex (3E33 and 3E37) obtained from the protein data bank. Molecular dynamics (MD) simulations were performed on the complexes, and different conformers of the same complex were generated. These conformers were undergone protein–ligand interaction fingerprint (PLIF) analysis, and the fingerprint bits have been used for structure-based pharmacophore model development. The PLIF results showed that Lys164, Tyr166, TrpB106 and TyrB361 are the major interacting residues in both the complexes. The RMSD and RMSF analyses on the MD-simulated systems showed that the absence of FPP in the complex 3E37 has significant effect in the conformational changes of the ligands. During this conformational change, some interactions between the protein and the ligands are lost, but regained after some simulations (after 2 ns). The structure-based pharmacophore models showed that the hydrophobic and acceptor contours are predominantly present in the models. The pharmacophore models were validated using reference compounds, which significantly identified as HITs with smaller RMSD values. The developed structure-based pharmacophore models are significant, and the methodology used in this study is novel from the existing methods (the original X-ray crystallographic coordination of the ligands is used for the model building). In our study, along with the original coordination of the ligand, different conformers of the same complex (protein–ligand) are used. It concluded that the developed methodology is significant for the virtual screening of novel molecules on different targets.  相似文献   
102.
103.
104.

Background

Arterial vascular anomalies in patients undergoing kidney transplantation (KT) are correlated with a higher incidence of early surgical complications, potentially causing graft loss. Arterial reconstruction allows patients to overcome these surgical challenges, thus minimizing the risk of poor outcomes. The aim of the present study is to retrospectively investigate the safety and effectiveness of the multiple arterial reconstruction technique with a Teflon patch in case of an unavailable aortic patch: to do so, surgical complications, graft function, and patient survival were evaluated.

Methods

During the period January 2009 to August 2016, 202 adult deceased-donor KTs were performed at our center. Group A (n = 27; reconstruction of multiple arteries) and Group B (n = 175; control group) were compared.

Results

No differences were observed between the 2 groups in terms of early postoperative course, with no vascular complication observed in Group A. No vascular patch infections were reported, nor longer cold ischemia time rates. Similarly, long-term survival rates were similar between the 2 groups.

Conclusions

The Teflon-patch arterial reconstruction technique appears to be safe and effective, with an acceptable balance of benefits and potential risks of using a prosthetic material. Studies based on larger series are needed to further validate this approach.  相似文献   
105.
106.
107.
108.
109.
BackgroundThe aim of this paper is to assess the current state of quality and outcomes measures being reported for hepatic resections in the recent literature.MethodsMedline and PubMed databases were searched for English language articles published between 1 January 2002 and 30 April 2013. Two examiners reviewed each article and relevant citations for appropriateness of inclusion, which excluded papers of liver donor hepatic resections, repeat hepatectomies or meta-analyses. Data were extracted and summarized by two examiners for analysis.ResultsFifty-five studies were identified with suitable reporting to assess peri-operative mortality in hepatic resections. In only 35% (19/55) of the studies was the follow-up time explicitly stated, and in 47% (26/55) of studies peri-operative mortality was limited to in-hospital or 30 days. The time period in which complications were captured was not explicitly stated in 19 out of 28 studies. The remaining studies only captured complications within 30 days of the index operation (8/28). There was a paucity of quality literature addressing truly patient-centred outcomes.ConclusionQuality outcomes after a hepatic resection are inconsistently reported in the literature. Quality outcome studies for a hepatectomy should report mortality and morbidity at a minimum of 90 days after surgery.  相似文献   
110.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号